Management indicated plans to provide both regulatory and clinical trial updates on blarcamesine for indications beyond Alzheimer’s, including Parkinson’s disease, Rett syndrome, and Fragile X.
The EU medicines agencies’ network strategy, EMANS, is an update of the five-year strategy previously developed to cover the period 2021 to 2025. The European Medicines Agency (EMA) and the Heads of ...
As I have talked about countless times on here, having an edge in the market directly correlates to having something unique that is not public, that no one else uses. It's always about thinking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results